Wedbush analyst Liana Moussatos reiterated a Buy rating on Pacira Pharmaceuticals (NASDAQ: PCRX) today and set a price target of $80. The company’s shares opened today at $33.95.
According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 8.9% and a 42.5% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Global Blood Therapeutics, and Catabasis Pharmaceuticals.
Pacira Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $45.
See today’s analyst top recommended stocks >>
Based on Pacira Pharmaceuticals’ latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $79.08 million and quarterly net profit of $4.6 million. In comparison, last year the company earned revenue of $69.28 million and had a GAAP net loss of $19.87 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company. It develops, commercializes, and manufactures pharmaceutical products for use in hospitals and ambulatory surgery centers. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.
